An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Novo Nordisk, the drugmaker behind Ozempic and Wegovy, has signed a deal with a company called Vivani to develop a long-lasting implant that would release semaglutide over time. In plain terms: instead of weekly or daily injections, the idea is a small device placed under the skin that slowly delivers the same medicine for weeks or months. The announcement is a business partnership; it doesn’t mean a product is on the market yet. Semaglutide is the active drug in Ozempic and Wegovy. It’s a man-made version of a gut hormone that helps control appetite and blood sugar. In people, it makes you feel fuller and slows how quickly your stomach empties, which can lead to weight loss and better blood sugar control. Right now it’s usually given as a once-weekly injection. An implant would be a different way to get the same medicine into the body over a longer period without regular shots. The news here is about development, not new clinical proof. Novo Nordisk and Vivani will work together to design and test an implant system that steadily releases semaglutide. The report doesn’t present study results showing the implant works in people yet. It also doesn’t say how long the implant would last, how well it would control drug levels, or when human trials might begin. So far this is a strategic move and a promise to try a different delivery method rather than evidence that the implant is safe or effective. Why this could matter is straightforward: many people find regular injections inconvenient or uncomfortable. A long-lasting implant could improve convenience and adherence (meaning people are more likely to keep getting the medicine as intended). That could be helpful for people using semaglutide for type 2 diabetes or for chronic weight management, where consistent dosing matters. It might also expand options for patients who struggle with self-injection. There are important caveats and risks. Implants require minor procedures to insert and remove, and they can cause local pain, infection, or device problems. We don’t yet know how well an implant would match the dosing control of injections, or whether side effects would change. Regulatory agencies would need data from human trials before approval, and the companies haven’t shared timing or trial details. People shouldn’t assume an implant version is available or safer; for now it’s a development project with unknown outcomes. Bottom line: Novo Nordisk and Vivani are teaming up to try to make a semaglutide implant, which could replace some injections if it proves safe and effective, but it’s still early and many questions remain.
Source: Pharmaceutical Technology